A rational basis for selection among drugs of the same class

Heart

Volumn 89, Issue 6, 2003, Pages 687-694

  Brown, Morris J ^a  

^a ADDENBROOKE S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN ANTAGONIST; ATENOLOL; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; BUCINDOLOL; CAPTOPRIL; CARVEDILOL; CERIVASTATIN; CHLORTALIDONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; HYDROCHLOROTHIAZIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LABETALOL; LISINOPRIL; LOSARTAN; METOPROLOL; NADOLOL; NEBIVOLOL; PINDOLOL; PRAVASTATIN; PROPRANOLOL; RAMIPRIL; RENIN; ROSUVASTATIN; SIMVASTATIN; TIMOLOL; UNINDEXED DRUG; VASODILATOR AGENT;

CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; COUGHING; DRUG COST; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; HEART FAILURE; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; MYOPATHY; PATIENT COMPLIANCE; PRIORITY JOURNAL; REVIEW; STROKE;

EID: 0038147456     PISSN: 13556037     EISSN: None     Source Type: Journal    
DOI: 10.1136/heart.89.6.687     Document Type: Review

References (21)

1. Lyons D, Webster J, Benjamin N. Effect af enalopril and quinapril on forearm vascular ACE in man. Eur J Clin Pharmacol 1997;51:373-8.
2. Landmesser U, Cai H, Dikalov S, et al. Role of p47 (phox) in vascular oxidative stress and hypertension caused by angiotensin II. Hypertension 2002;40:511-5.
3. Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The heart outcomes prevention evaluation study investigators. N Engl J Med 2000;342:145-53. Landmark study showing that overall risk rather than individual risk factor should be the prime indication for additional treatment in the secondary prevention of vascular disease.
4. Anon. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet 2001;358:1033-41. Similar message to previous reference, this time for patients with previous stroke. PROGRESS showed more clearly than HOPE that blood pressure reduction from any level is beneficial in high risk patients.
5. Svensson P, de Faire U, Sleight P, et al. Comparative effects of ramipril on ambulatory and office blood pressures: a HOPE substudy. Hypertension 2001;38:28e-32.
6. Brown MJ. Matching the right drug to the right patient in hypertension. Heart 2001;86:113-20.
7. Morice AH, Lowry R, Brown MJ, et al. Angiotensin-converting enzyme and the cough reflex. Lancet 1987;2:1116-8.
8. Mazzolai L, Maillard M, Rossat J, et al. Angiotensin II receptor blockade in normotensive subjects: a direct comparison of three AT1 receptor antagonists. Hypertension 1999;33:850-5.
9. Conlin PR, Spence JD, Williams B, et al. Angiotensin II antagonists for hypertension: are there differences in efficacy? Am J Hypertens 2000;13:418-26.
10. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001;345:851-60. One of a trio of studies, published together, showing that the nephroprotective effect of angiotensin blockade is additional to the benefit predicted from blood pressure reduction.
11. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345:861-9.
12. Dahlof B, Devereux RB, Kjeldsen SE, et al. The losartan intervention for endpoint reduction in hypertension study. Lancet 2002;359:995-1003. First comparison of antihypertensive drugs to show a difference in primary outcome. The combination of β blockade and diuretic appears undesirable in older patients at risk of stroke or diabetes.
13. Medical Research Council, British Heart Foundation. MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:7-22. Another landmark study showing the importance of treating risk, rather than risk factor. LDL reduction from any level achieved large reductions in coronary disease and stroke.
14. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995;333:1301-7.
15. Schwartz GG, Olsson AG, Ezekowitz MD, et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes. The MIRACL study: a randomized controlled trial. JAMA 2001;285:1711-8.
16. 2 receptors are activated by high concentrations of adrenaline in patients with myocardial infarction or heart failure.
17. Brown MJ. To β block or better block? BMJ 1995;311:701-2.
18. Kelly R, Daley J, Avolio A, et al. Arterial dilation and reduced wave reflection. Benefit of dilevalol in hypertension. Hypertension 1989;14:14-21.
19. CIBIS II Investigators. The cardiac insufficiency bisoprolol study II (CIBIS-II): a randomised trial. Lancet 1999;353:9-13.
20. Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. US carvedilol heart failure study group. N Engl J Med 1996;334:1349-55. The first of several double blind, placebo controlled outcome studies to demonstrate substantial reduction in mortality when patients with heart failure are treated with β blockade.
21. Packer M, Coats AJ, Fowler MB, et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 2001;344:1651-8.